Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Jun;15 Suppl 1(s1):1-15.
doi: 10.1111/j.1365-3156.2010.02508.x.

Patient retention in antiretroviral therapy programs up to three years on treatment in sub-Saharan Africa, 2007-2009: systematic review

Matthew P Fox  1 , Sydney Rosen
Affiliations
Free PMC article

Patient retention in antiretroviral therapy programs up to three years on treatment in sub-Saharan Africa, 2007-2009: systematic review

Matthew P Fox et al. Trop Med Int Health. 2010 Jun.
Free PMC article

Abstract

Objectives: To estimate the proportion of all-cause adult patient attrition from antiretroviral therapy (ART) programs in service delivery settings in sub-Saharan Africa through 36 months on treatment.

Methods: We identified cohorts within Ovid Medline, ISI Web of Knowledge, Cochrane Database of Systematic Reviews and four conference abstract archives. We summarized retention rates from studies describing observational cohorts from sub-Saharan Africa reporting on adult HIV 1- infected patients initiating first-line three-drug ART. We estimated all-cause attrition rates for 6, 12, 18, 24, or 36 months after ART initiation including patients who died or were lost to follow-up (as defined by the author), but excluding transferred patients.

Results: We analysed 33 sources describing 39 cohorts and 226 307 patients. Patients were more likely to be female (median 65%) and had a median age at initiation of 37 (range 34-40). Median starting CD4 count was 109 cells/mm(3). Loss to follow-up was the most common cause of attrition (59%), followed by death (41%). Median attrition at 12, 24 and 36 months was 22.6% (range 7%-45%), 25% (range 11%-32%) and 29.5% (range 13%-36.1%) respectively. After pooling data in a random-effects meta-analysis, retention declined from 86.1% at 6 months to 80.2% at 12 months, 76.8% at 24 months and 72.3% at 36 months. Adjusting for variable follow-up time in a sensitivity analysis, 24 month retention was 70.0% (range: 66.7%-73.3%), while 36 month retention was 64.6% (range: 57.5%-72.1%).

Conclusions: Our findings document the difficulties in retaining patients in care for lifelong treatment, and the progress being made in raising overall retention rates.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Literature Search and Application of Eligibility Criteria in a Systematic Review of Retention in Antiretroviral Therapy Programs in Sub-Saharan Africa.
Figure 2
Figure 2
a–d Forest Plots of Reported Retention at 6, 12, 24 and 36 Months after Initiation of Antiretroviral Therapy in Sub-Saharan Africa*. *Pooled estimates were created using random-effects meta-analysis. Data include both actual reported rates for studies that reported to each time point and linear interpolation for studies which reported to a later time point but not the current time point.
Figure 3
Figure 3
Weighted Average Retention Rates Over Time in Antiretroviral Therapy Programs in Sub-Saharan Africa*. *Studies reporting later time points and not earlier ones had the earlier attrition rates interpolated as described in the methods section and then weighted by cohort size.
Figure 4
Figure 4
Projected Retention Rates Over Time in Antiretroviral Therapy Programs in Sub-Saharan Africa Using Varying Assumptions*. *Best-case scenario uses last observation carried forward and assumes no additional attrition after the last time point reported to. Worst-case scenario assumes a continued linear decline from the last time point reported to through 36 months. The mid-point scenario is the average of the best and worst-case scenarios. Studies are weighted by their sample size.
See this image and copyright information in PMC

Comment in

References

    1. Ahoua L, Guenther G, Pinoges L, et al. Risk factors for virological failure and subtherapeutic antiretroviral drug concentrations in HIV-positive adults treated in rural northwestern Uganda. BMC Infectious Diseases. 2009;9:81. - PMC - PubMed
    1. Anglaret X, Toure S, Gourvellec G, et al. Impact of vital status investigation procedures on estimates of survival in cohorts of HIV-infected patients from Sub-Saharan Africa. Journal of Acquired Immune Deficiency Syndromes. 2004;35:320–323. - PubMed
    1. Auld AF. Treatment Outcomes of HIV-Infected Adults Enrolled in the National Antiretroviral Therapy Program -Mozambique, 2004-2007. Namibia: HIV/AIDS Implementers' Meeting Windhoek; 2009. (Abstract 1608)
    1. Badri M, Cleary S, Maartens G, et al. When to initiate highly active antiretroviral therapy in sub-Saharan Africa? A South African cost-effectiveness study. Antiviral Therapy. 2006;11:63–72. - PubMed
    1. Bajunirwe F, Arts EJ, Tisch DJ, Debanne SM, Sethi AK. Survival, Adherence to Care and Antiretroviral Treatment (ART) Among HIV-Infected Adults in Rural Western Uganda. 2007. 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention WEPEB049.

Publication types